As Cross-Species Transplantation Forges Ahead, Some Researchers Call For Caution

Within just a few years, a growing number of surgeons expect to be able to transplant cells, tissues, and organs from baboons, pigs, and other animals into humans as accepted therapy for a number of life-threatening conditions and diseases. Driven by scientific innovation and powerful medical need, the field of cross-species transplantation, or xenotransplantation, is moving ahead with several ground-breaking experimental human procedures this year, and more expected in the near future. EXERC

Written byFranklin Hoke
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Within just a few years, a growing number of surgeons expect to be able to transplant cells, tissues, and organs from baboons, pigs, and other animals into humans as accepted therapy for a number of life-threatening conditions and diseases. Driven by scientific innovation and powerful medical need, the field of cross-species transplantation, or xenotransplantation, is moving ahead with several ground-breaking experimental human procedures this year, and more expected in the near future.

Thomas EXERCISING RESTRAINT: Thomas E. Starzl has put the University of Pittsburgh xenotransplantation program onhold pending a better understanding of the problems.

Infectious disease experts have raised public health warnings about new viruses with epidemic potential that may piggyback on the transfers from animals to humans. Some researchers--including several responsible for major advances in transplantation in the past--say that the current scientific base is insufficient to support experimental xenotransplantation involving humans. They fear that, unless those within the transplantation ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies